Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK - Concepedia

Concepedia

Publication | Open Access

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK

DOI Full Paper Access

24

Citations

21

References

2020

Year

Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova, Syed Raza, Shamika U. de Silva, Mark Lamotte

Diabetes Therapy

Abstract

Empagliflozin 25 mg is a cost-effective treatment option versus oral semaglutide 14 mg, when used in addition to metformin, for the treatment of T2DM patients in the UK.

References

	Year	Citations

Page 1